Jul 2026· International Journal of Molecular Sciences· Vol 27· 0 citations· 194 references
Medicine
TL;DR
This review provides an updated overview of cyclic peptides as modulators of PPIs, outlining current opportunities, methodological advances, and remaining challenges in the development of cyclic peptide-based PPI modulators.
Abstract
Protein–protein interactions (PPIs) represent a vast and largely underexplored landscape of therapeutic targets, yet their structural features—including large, flat, and dynamic interfaces—have historically limited their druggability. In this context, cyclic peptides have emerged as a powerful class of PPI modulators, sitting at the interface between biologics and small molecules, and thus garnering key advantages of both classes. Their conformational constraint enhances binding affinity, proteolytic stability and, in some instances, cell permeability, thus enabling access to intracellular targets. This review provides an updated overview of cyclic peptides as modulators of PPIs, focusing on both conceptual foundations and practical strategies for their discovery and optimization. The main discovery approaches include natural sources, de novo design based on secondary structure mimetics, high-throughput screening, and computational approaches. Integration of these complementary strategies is crucial to enhance success rates in the discovery of effective and developable cyclic peptides. Accordingly, the present review aims to provide a practical guide for researchers entering this rapidly growing field, outlining current opportunities, methodological advances, and remaining challenges in the development of cyclic peptide-based PPI modulators.
A framework for accelerating the development of next-generation PPI therapeutics is provided by connecting interface architecture with optimal inhibitor modality and discovery strategy, revealing clear links between interface topology and inhibitor discovery strategies.
Ellie Hyde, A. Beekman· RSC Medicinal Chemistry· 0 citations
Natural cyclic peptides have long served as a rich reservoir of bioactivity, occupying a unique region of the drug space that bridges the gap between small molecules and large biologics, and researchers are rationally engineering next-generation macrocycles, positioning them at the frontier of modern drug development.
Greta Bergamaschi, Giulia Lodigiani, Stefano Gandolfi et al.· Current Opinion in Chemical...· 0 citations
HighMorph is presented, an interaction-guided framework that combines protein–protein interaction information with artificial intelligence for rational cyclic peptide design and provides insights for developing therapeutics targeting challenging protein interfaces.
M. Lan, Cheng-Yun Zhang, Wentong Wang et al.· Journal of Medicinal Chemist...· 0 citations
This report analyzes trends in cyclic peptide research using data from the CAS Content Collection over the past two decades to provide a comprehensive view of the evolving cyclic peptide landscape and emerging principles guiding their future development.
T. Thite, Kavita A. Iyer, Preeti Jain et al.· Journal of Medicinal Chemist...· 0 citations
The structural and medicinal chemistry principles underlying (i) allosteric inhibition and (ii) proximity-induced degradation are summarized, with an emphasis on design logic, structure-activity relationships, and key liabilities in the beyond rule of five space.
Mei Zhou, Linshan Li, Xiao-Juan Tang et al.· Future Medicinal Chemistry· 0 citations
A protocol for discovering protein‐binding peptides using a very large, target‐agnostic yeast surface display library containing approximately 6.1 × 109 unique clones and providing broad coverage of short peptide sequence space is described.
J. D. Hurley, Andrew C. Kruse· Current Protocols· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.